PMID- 37608889
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20231106
IS  - 1663-9812 (Print)
IS  - 1663-9812 (Electronic)
IS  - 1663-9812 (Linking)
VI  - 14
DP  - 2023
TI  - Efficacy and safety of Tripterygium wilfordii multiglucoside for idiopathic 
      membranous nephropathy: a systematic review with bayesian meta-analysis.
PG  - 1183499
LID - 10.3389/fphar.2023.1183499 [doi]
LID - 1183499
AB  - Background: Currently, the optimal therapy plan for idiopathic membranous 
      nephropathy (IMN) remains controversial as there has been no comprehensive and 
      systematic comparison of therapy plans for IMN. Therefore, in this study, a 
      Bayesian meta-analysis was used to systematically evaluate the clinical efficacy 
      and safety of various intervention plans involving traditional Chinese medicine 
      TWM in the treatment of IMN. Methods: An electronic search in 7 databases was 
      conducted from their inception to August 2022 for all published randomized 
      controlled trials (RCTs) of various intervention plans for IMN. Network 
      meta-analysis (NMA) was performed by using software R, and the surface under the 
      cumulative ranking area (SUCRA) probability curve was plotted for each outcome 
      indicator to rank the efficacy and safety of different intervention plans. 
      Results: A total of 30 RCTs were included, involving 13 interventions. The 
      results showed that (1) in terms of total remission (TR), 1 in circle GC + CNI + TWM was 
      the best effective among all plans, and the addition and subtraction plan of CNI 
      + TWM was the best effective for IMN; 2 in circle All plans involving TWM were more 
      effective than GG; 3 in circle Among monotherapy plans for IMN, TWM was more effective 
      distinctly than GC, while TWM and CNI were similarly effective; 4 in circle Among multidrug 
      therapy plans for IMN, the addition of TWM to previously established therapy 
      plans made the original plans more effective; ⑤The efficacy of combining TWM with 
      other plans was superior to that of TWM alone. (2) In terms of lowering 24 h-UTP, 
      GC + TWM was the best effective and more effective than TWM. (3) In terms of 
      safety, there was no statistically significant difference between all groups. 
      However, CNI + TWM was the safest. No serious adverse events (AEs) occurred in 
      all the included studies. Conclusion: The addition of TWM may be beneficial to 
      patients with IMN. It may enhance the efficacy of previously established 
      treatment protocols without leading to additional safety risks. In particular, GC 
      + CNI + TWM, GC + TWM, and CNI + TWM with better efficacy and higher safety can 
      be preferred in clinical decision-making as the therapy plans for IMN.
CI  - Copyright (c) 2023 Wang, Liu, Xue, Wang and Yuan.
FAU - Wang, Hongyun
AU  - Wang H
AD  - Hubei University of Chinese Medicine, Wuhan, China.
FAU - Liu, Hongyan
AU  - Liu H
AD  - Department of Nephrology, Renmin Hospital of Wuhan University, Wuhan, China.
FAU - Xue, Xue
AU  - Xue X
AD  - Hubei University of Chinese Medicine, Wuhan, China.
FAU - Wang, Qiong
AU  - Wang Q
AD  - Hubei University of Chinese Medicine, Wuhan, China.
FAU - Yuan, Jun
AU  - Yuan J
AD  - Department of Nephrology, Renmin Hospital of Wuhan University, Wuhan, China.
LA  - eng
PT  - Journal Article
DEP - 20230802
PL  - Switzerland
TA  - Front Pharmacol
JT  - Frontiers in pharmacology
JID - 101548923
PMC - PMC10442163
OTO - NOTNLM
OT  - Tripterygium wilfordii Hook.f. (Celastraceae)
OT  - adverse effects
OT  - immunosuppression
OT  - membranous nephropathy
OT  - network meta-analysis
COIS- The authors declare that the research was conducted in the absence of any 
      commercial or financial relationships that could be construed as a potential 
      conflict of interest.
EDAT- 2023/08/23 06:42
MHDA- 2023/08/23 06:43
PMCR- 2023/08/02
CRDT- 2023/08/23 03:51
PHST- 2023/03/10 00:00 [received]
PHST- 2023/07/24 00:00 [accepted]
PHST- 2023/08/23 06:43 [medline]
PHST- 2023/08/23 06:42 [pubmed]
PHST- 2023/08/23 03:51 [entrez]
PHST- 2023/08/02 00:00 [pmc-release]
AID - 1183499 [pii]
AID - 10.3389/fphar.2023.1183499 [doi]
PST - epublish
SO  - Front Pharmacol. 2023 Aug 2;14:1183499. doi: 10.3389/fphar.2023.1183499. 
      eCollection 2023.